NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour. For patients with inoperable disease, few treatment options are available after first line chemotherapy. The combination of ipilimumab and nivolumab has recently shown increased survival compared to standard chemothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Haakensen, Vilde Drageset, Nowak, Anna K., Ellingsen, Espen Basmo, Farooqi, Saima Jamil, Bjaanæs, Maria Moksnes, Horndalsveen, Henrik, Mcculloch, Tine, Grundberg, Oscar, Cedres, Susana M., Helland, Åslaug
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165504/
https://www.ncbi.nlm.nih.gov/pubmed/34059094
http://dx.doi.org/10.1186/s12967-021-02905-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165504/
https://www.ncbi.nlm.nih.gov/pubmed/34059094
http://dx.doi.org/10.1186/s12967-021-02905-3

Ejemplares similares